. Author manuscript; available in PMC: 2021 Sep 1.

Published in final edited form as: Mech Ageing Dev. 2020 Jun 28;190:111297. doi: 10.1016/j.mad.2020.111297

Table 4.

Effect of compounds on Huntington’s disease

Compound	Cell Culture	C. elegans	Drosophila	Mouse	Human
Metformin	Protective¹	Protective^{2, 3}	N/A	Protective^{2, 4, 5}	Protective⁶
Resveratrol	Protective^{7, 8}	Protective⁷	Protective^{9, 10}	Protective^{8, 11, 12}	N/A
Rapamycin	Protective^{13, 14}	N/A	Protective¹⁵	Protective¹⁵ No effect¹⁶	N/A
NAC	N/A	N/A	N/A	Protective^{17, 18}	N/A
Curcumin	N/A	N/A	Protective¹⁹	Protective²⁰	N/A

^1.

Jin J, et al. (2016) Neuromolecular Med 18(4).

^2.

Sanchis A, et al. (2019) Exp Mol Med 51(6).

^3.

Vázquez-Manrique RP, et al. (2016) Hum Mol Genet 25(6).

^4.

Arnoux I, et al. (2018) Elife 7.

^5.

Ma TC, et al. (2007) Neurosci Lett 411(2).

^6.

Hervás D, et al. (2017) PloS one 12(6).

^7.

Parker JA, et al. (2005) Nature genetics 37(4).

^8.

Naia L, et al. (2017) Molecular neurobiology 54(7).

^9.

Pallos J, et al. (2008) Human molecular genetics 17(23).

^10.

Maher P, et al. (2011) Human molecular genetics 20(2).

^11.

Ho DJ, et al. (2010) Experimental neurology 225(1).

^12.

Gerhardt E, et al. (2011) PloS one 6(12).

^13.

Ravikumar BD, R.; Rubinsztein, C. (2002) Hum Mol Genet 11.

^14.

King MA, et al. (2008) Mol Pharmacol 73(4).

^15.

Ravikumar B, et al. (2004) Nat Genet 36(6).

^16.

Fox JH, et al. (2010) Mol Neurodegener 5.

^17.

Sandhir R, et al. (2012) Neurodegenerative Diseases 9(3).

^18.

Wright DJ, et al. (2015) Translational Psychiatry 5(1).

^19.

Chongtham A, et al. (2016) Sci Rep 6.

^20.

Hickey MA, et al. (2012) Mol Neurodegener 7.